Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress

被引：3
作者：
Wu, Hong-Yu [1 ]
Li, Jin-Wei [2 ]
Li, Jin-Zheng [1 ]
Zhai, Qi-Long [1 ]
Ye, Jing-Yuan [1 ]
Zheng, Si-Yuan [1 ]
Fang, Kun [3 ]
机构：
[1] Chongqing Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 2, Chongqing 400010, Peoples R China
[2] Guangxi Med Univ, Dept Neurosurg, Affiliated Hosp 4, Liuzhou 545000, Guangxi, Peoples R China
[3] Yinchuan Maternal & Child Hlth Hosp, Dept Surg, 56 Wenhua West Rd, Yinchuan 750000, Ningxia, Peoples R China
来源：
WORLD JOURNAL OF GASTROINTESTINAL SURGERY | 2023年 / 15卷 / 02期
关键词：
Borderline resectable pancreatic cancer; Neoadjuvant therapy; Resectability; Surgery; Multimodality treatment; Multidisciplinary teams; LONG-TERM OUTCOMES; PREOPERATIVE CHEMORADIATION THERAPY; INTERNATIONAL STUDY-GROUP; CT TEXTURE ANALYSIS; PHASE-II TRIAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT THERAPY; RADIATION-THERAPY; CONSENSUS STATEMENT; VASCULAR RESECTION;
D O I：
10.4240/wjgs.v15.i2.142
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Borderline resectable pancreatic cancer (BRPC) is a complex clinical entity with specific biological features. Criteria for resectability need to be assessed in combination with tumor anatomy and oncology. Neoadjuvant therapy (NAT) for BRPC patients is associated with additional survival benefits. Research is currently focused on exploring the optimal NAT regimen and more reliable ways of assessing response to NAT. More attention to management standards during NAT, including biliary drainage and nutritional support, is needed. Surgery remains the cornerstone of BRPC treatment and multidisciplinary teams can help to evaluate whether patients are suitable for surgery and provide individualized management during the perioperative period, including NAT responsiveness and the selection of surgical timing.
引用
收藏
页码：142 / 162
页数：21
相关论文
共 158 条
  • [1] Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
    Ahmad, Syed A.
    Duong, Mai
    Sohal, Davendra P. S.
    Gandhi, Namita S.
    Beg, Muhammad Shaalan
    Wang-Gillam, Andrea
    Wade, James L., III
    Chiorean, Elena Gabriela
    Guthrie, Katherine A.
    Lowy, Andrew M.
    Philip, Philip A.
    Hochster, Howard S.
    [J]. ANNALS OF SURGERY, 2020, 272 (03) : 481 - 486
  • [2] FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
    Akita, H.
    Takahashi, H.
    Ohigashi, H.
    Tomokuni, A.
    Kobayashi, S.
    Sugimura, K.
    Miyoshi, N.
    Moon, J. -H.
    Yasui, M.
    Omori, T.
    Miyata, H.
    Ohue, M.
    Fujiwara, Y.
    Yano, M.
    Ishikawa, O.
    Sakon, M.
    [J]. EJSO, 2017, 43 (06): : 1061 - 1067
  • [3] Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association
    Al-Hawary, Mahmoud M.
    Francis, Isaac R.
    Chari, Suresh T.
    Fishman, Elliot K.
    Hough, David M.
    Lu, David S.
    Macari, Michael
    Megibow, Alec J.
    Miller, Frank H.
    Mortele, Koenraad J.
    Merchant, Nipun B.
    Minter, Rebecca M.
    Tamm, Eric P.
    Sahani, Dushyant V.
    Simeone, Diane M.
    [J]. GASTROENTEROLOGY, 2014, 146 (01) : 291 - +
  • [4] PORTAL-VEIN RESECTION IN PATIENTS UNDERGOING PANCREATICODUODENECTOMY FOR CARCINOMA OF THE PANCREATIC HEAD
    ALLEMA, JH
    REINDERS, ME
    VANGULIK, TM
    VANLEEUWEN, DJ
    DEWIT, LT
    VERBEEK, PCM
    GOUMA, DJ
    [J]. BRITISH JOURNAL OF SURGERY, 1994, 81 (11) : 1642 - 1646
  • [5] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
    Allemani, Claudia
    Matsuda, Tomohiro
    Di Carlo, Veronica
    Harewood, Rhea
    Matz, Melissa
    Niksic, Maja
    Bonaventure, Audrey
    Valkov, Mikhail
    Johnson, Christopher J.
    Esteve, Jacques
    Ogunbiyi, Olufemi J.
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Eser, Sultan
    Engholm, Gerda
    Stiller, Charles A.
    Monnereau, Alain
    Woods, Ryan R.
    Visser, Otto
    Lim, Gek Hsiang
    Aitken, Joanne
    Weir, Hannah K.
    Coleman, Michel P.
    [J]. LANCET, 2018, 391 (10125) : 1023 - 1075
  • [6] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Alva-Ruiz, Roberto
    Yohanathan, Lavanya
    Yonkus, Jennifer A.
    Abdelrahman, Amro M.
    Gregory, Lindsey A.
    Halfdanarson, Thorvadur R.
    Mahipal, Amit
    McWilliams, Robert R.
    Ma, Wen Wee
    Hallemeier, Christopher L.
    Graham, Rondell P.
    Grotz, Travis E.
    Smoot, Rory L.
    Cleary, Sean P.
    Nagorney, David M.
    Kendrick, Michael L.
    Truty, Mark J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1579 - 1591
  • [7] Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
    Alvarez, R.
    Musteanu, M.
    Garcia-Garcia, E.
    Lopez-Casas, P. P.
    Megias, D.
    Guerra, C.
    Munoz, M.
    Quijano, Y.
    Cubillo, A.
    Rodriguez-Pascual, J.
    Plaza, C.
    de Vicente, E.
    Prados, S.
    Tabernero, S.
    Barbacid, M.
    Lopez-Rios, F.
    Hidalgo, M.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 926 - 933
  • [8] Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients
    Aoki, Shuichi
    Motoi, Fuyuhiko
    Murakami, Yoshiaki
    Sho, Masayuki
    Satoi, Sohei
    Honda, Goro
    Uemura, Kenichiro
    Okada, Ken-ichi
    Matsumoto, Ippei
    Nagai, Minako
    Yanagimoto, Hiroaki
    Kurata, Masanao
    Fukumoto, Takumi
    Mizuma, Masamichi
    Yamaue, Hiroki
    Unno, Michiaki
    [J]. BMC CANCER, 2019, 19 (1)
  • [9] Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio
    Asiyanbola, Bolanle
    Gleisner, Ana
    Herman, Joseph M.
    Choti, Michael A.
    Wolfgang, Christopher L.
    Swartz, Michael
    Edil, Barish H.
    Schulick, Richard D.
    Cameron, John L.
    Pawlik, Timothy M.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (04) : 752 - 759
  • [10] Beyond imaging: The promise of radiomics
    Avanzo, Michele
    Stancanello, Joseph
    El Naqa, Issam
    [J]. PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2017, 38 : 122 - 139
12345678910